Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.

Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, Ory PA, Peterfy CG, Fuerst T, Wang H, Zhou L, Tsuji W, Newmark R.

Arthritis Care Res (Hoboken). 2010 Apr;62(4):569-74. doi: 10.1002/acr.20004.

2.

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R; Denosumab Rheumatoid Arthritis Study Group.

Arthritis Rheum. 2008 May;58(5):1299-309. doi: 10.1002/art.23417.

3.

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.

Arthritis Rheum. 2007 Feb;56(2):476-88.

4.

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.

Arthritis Rheum. 2005 Oct;52(10):3279-89.

5.

Psoriatic arthritis and imaging.

Ory PA, Gladman DD, Mease PJ.

Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii55-7. Review.

6.

Interpreting radiographic data in rheumatoid arthritis.

Ory PA.

Ann Rheum Dis. 2003 Jul;62(7):597-604. Review.

7.

Radiography in the assessment of musculoskeletal conditions.

Ory PA.

Best Pract Res Clin Rheumatol. 2003 Jun;17(3):495-512. Review.

PMID:
12787514
8.

A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes.

Clark MR, Stuart SG, Kimberly RP, Ory PA, Goldstein IM.

Eur J Immunol. 1991 Aug;21(8):1911-6.

PMID:
1831131
9.

Transfected NA1 and NA2 forms of human neutrophil Fc receptor III exhibit antigenic and structural heterogeneity.

Ory PA, Clark MR, Talhouk AS, Goldstein IM.

Blood. 1991 Jun 15;77(12):2682-7.

PMID:
1710518
10.

An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus.

Clark MR, Liu L, Clarkson SB, Ory PA, Goldstein IM.

J Clin Invest. 1990 Jul;86(1):341-6.

11.

Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils.

Ory PA, Clark MR, Kwoh EE, Clarkson SB, Goldstein IM.

J Clin Invest. 1989 Nov;84(5):1688-91.

12.

Molecular basis for a polymorphism involving Fc receptor II on human monocytes.

Clark MR, Clarkson SB, Ory PA, Stollman N, Goldstein IM.

J Immunol. 1989 Sep 1;143(5):1731-4.

PMID:
2527271
13.

Characterization of polymorphic forms of Fc receptor III on human neutrophils.

Ory PA, Goldstein IM, Kwoh EE, Clarkson SB.

J Clin Invest. 1989 May;83(5):1676-81.

14.

Supplemental Content

Support Center